Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: BioNTech 0.114, AstraZeneca 15.384.
BioNTech vs AstraZeneca Net Worth and Market Cap
BioNTech (BNTX) and AstraZeneca (AZN) are peers in Vaccines. BioNTech reported revenue of $114M as of Q2 2026, compared with $15.4B for AstraZeneca. AstraZeneca leads on revenue.
BioNTech's gross margin is 8.1% versus 83.6% for AstraZeneca. BioNTech's net margin is -777.3% versus 16.3% for AstraZeneca.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: AstraZeneca +6.4%, BioNTech -59.6%.
- AstraZeneca made an operating profit in its latest quarter (20.6% margin); BioNTech made an operating loss (-897.8%).
- BioNTech's KPIs on Sterling include Cash, Cash Equivalents, and Security Investments (Quarterly) and COMIRNATY Doses as Printed.
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, BioNTech, AstraZeneca.| Metric | BioNTech | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $114.00M | $15.38B |
| Cost of Revenue | $105.00M | $2.52B |
| Gross Profit | $9.00M | $12.86B |
| Operating Income | $-1.02B | $3.16B |
| Net Income | $-886.00M | $2.51B |
| R&D Expense | $595.00M | $4.05B |
| Earnings Per Share | -$3.5 | $1.59 |
| Gross Margin | 8.1% | 83.6% |
| Operating Margin | -897.8% | 20.6% |
| Net Profit Margin | -777.3% | 16.3% |
| Free Cash Flow | $-48.00M | $2.13B |
| Cumulative Free Cash Flow | $19.56B | $121.22B |
| Operating Cash Flow | $12.00M | $2.89B |
| Cash & Equivalents | $10.52B | $4.89B |